Hydralazine
Research News and Information

Monday, November 23, 2009

Heart failure in women: a need for prospective data.

2 Aug 2009 Heart failure affects 5 million Americans, and nearly 50% of these are women. Sex differences have been noted regarding the underlying etiology, pathophysiology, and prognosis. Women are less likely to have coronary artery disease and more likely ... Read more...

Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure.

18 Jul 2009 Hypertension-induced diastolic heart failure accounts for a large proportion of all heart failure presentations. Hypertension also induces left ventricular (LV) hypertrophy. Fixed-dose isosorbide dinitrate/hydralazine (HISDN) decreased mortality in ... Read more...

The effect of recombinant aminopeptidase A (APA) on hypertension in pregnant spontaneously hypertensive rats (SHRs).

14 Jul 2009 BACKGROUND: We have tested the effects of aminopeptidase A (APA), MgSO(4) and various conventional antihypertensive drugs on hypertension in pregnant spontaneously hypertensive rats (SHRs) and examined the effects on both fetal heart and kidney. ... Read more...

Latest indexed articles for 'Hydralazine'

These are the very latest articles for this heading:

• Heart failure in women: a need for prospective data. 2 Aug 2009
• Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure. 18 Jul 2009
• The effect of recombinant aminopeptidase A (APA) on hypertension in pregnant spontaneously hypertensive rats (SHRs). 14 Jul 2009
• Covalent binding of penicillamine to macrophages: implications for penicillamine-induced autoimmunity. 29 Jun 2009
• Hydralazine-induced cholestatic hepatitis. 29 Jun 2009
• Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats. 22 May 2009
• Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. 6 May 2009
• Evidence for a noradrenergic mechanism causing hypertension and abnormal glucose metabolism in rats with relative deficiency of gamma-melanocyte-stimulating hormone. 6 May 2009
• Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1. 29 Apr 2009
• Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat. 30 Mar 2009
• Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure. 27 Feb 2009
• Have we witnessed the rise and fall of race-specific drugs? 27 Feb 2009
• Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics. 27 Feb 2009
• ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. 25 Feb 2009
• Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. 24 Feb 2009
• Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. 19 Feb 2009
• Pharmacotherapeutic options for the treatment of preeclampsia. 13 Feb 2009
• Inhibition of nitric oxide synthases abrogates pregnancy-induced uterine vascular expansive remodeling. 8 Feb 2009
• Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. 19 Jan 2009
• Bioactivation of organic nitrates and the mechanism of nitrate tolerance. 30 Dec 2008

See a longer list of these articles.

Technical information about 'Hydralazine'

Definition: A direct-acting vasodilator that is used as an antihypertensive agent.

Chemical name: 1(2H)-Phthalazinone, hydrazone

Registry Number: 86-54-4

Descriptor UI: D006830

Alternative terms: Hydralazine; Hydrallazin; Hydrazinophthalazine; Apressin; Nepresol; Hydralazine mono-Hydrochloride; Hydralazine mono Hydrochloride; mono-Hydrochloride, Hydralazine; Apressoline; Apresoline; Hydralazine Hydrochloride; Hydrochloride, Hydralazine;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antihypertensive Agents; Vasodilator Agents;

Tree Number: D03.383.710.605.500;